The DOI matches its Crossref record; 266 of the 266 references it cites were found in a registry or an index.
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
Open accessAbstract
Triple-negative breast cancer (TNBC), characterized by the absence or low expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2), is the most aggressive subtype of breast cancer. TNBC accounts for about 15% of breast cancer cases in the U.S., and is known for high relapse rates and poor overall survival (OS). Chemo-resistant TNBC is a genetically diverse, highly heterogeneous, and rapidly evolving disease that challenges our ability to individualize treatment for incomplete responders and relapsed patients. Currently, the frontline standard chemotherapy, composed of anthracyclines, alkylating agents, and taxanes, is commonly used to treat high-risk and locally advanced TNBC. Several FDA-approved drugs that target programmed cell death protein-1 (Keytruda) and programmed death ligand-1 (Tecentriq), poly ADP-ribose polymerase (PARP), and/or antibody drug conjugates (Trodelvy) have shown promise in improving clinical outcomes for a subset of TNBC. These inhibitors that target key genetic mutations and specific molecular signaling pathways that drive malignant tumor growth have been used as single agents and/or in combination with standard chemotherapy regimens. Here, we review the current TNBC treatment options, unmet clinical needs, and actionable drug targets, including epidermal growth factor (EGFR), vascular endothelial growth factor (VEGF), androgen receptor (AR), estrogen receptor beta (ERβ), phosphoinositide-3 kinase (PI3K), mammalian target of rapamycin (mTOR), and protein kinase B (PKB or AKT) activation in TNBC. Supported by strong evidence in developmental, evolutionary, and cancer biology, we propose that the K-RAS/SIAH pathway activation is a major tumor driver, and SIAH is a new drug target, a therapy-responsive prognostic biomarker, and a major tumor vulnerability in TNBC. Since persistent K-RAS/SIAH/EGFR pathway activation endows TNBC tumor cells with chemo-resistance, aggressive dissemination, and early relapse, we hope to design an anti-SIAH-centered anti-K-RAS/EGFR targeted therapy as a novel therapeutic strategy to control and eradicate incurable TNBC in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Siegel, R. L., Miller, K. D., & Jemal, A. (2020) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21590 · Cited by 20,444
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
Siegel, R. L., Miller, K. D., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21332 · Cited by 16,003
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Nishimura, R., Osako, T., Nishiyama, Y., Tashima, R., Nakano, M., Fujisue, M., Toyozumi, Y., & Arima, N. (2013) · Oncology · doi:10.1159/000353099 · Cited by 13,166
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Amin, M. B., Greene, F. L., Edge, S. B., Compton, C. C., Gershenwald, J. E., Brookland, R. K., Meyer, L., Gress, D. M., Byrd, D. R., & Winchester, D. P. (2017) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21388 · Cited by 6,502
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887
Lehmann, B. D., Bauer, J. A., Chen, X., Sanders, M. E., Chakravarthy, A. B., Shyr, Y., & Pietenpol, J. A. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45014 · Cited by 5,592
Triple-negative breast cancer: clinical features and patterns of recurrence
Dent, R., Trudeau, M., Pritchard, K. I., Hanna, W. M., Kahn, H. K., Sawka, C. A., Lickley, L. A., Rawlinson, E., Sun, P., & Narod, S. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-3045 · Cited by 5,091 · cited 1×
“Depending on their response to initial chemotherapy, one in three TNBC patients will develop tumor recurrence, which typically occurs within the first three years of initial diagnosis, and persistently, one in five TNBC patients will succumb to their metastatic disease in less than five years [21,22,26].”
BackgroundThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Cortazar, P., Zhang, L., Untch, M., Mehta, K., Costantino, J. P., Wolmark, N., Bonnefoi, H., Cameron, D., Gianni, L., Valagussa, P., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)62422-8 · Cited by 4,742
Elkablawy, M. A., Albasri, A. M., Mohammed, R. A., Hussainy, A. S., Nouh, M. M., & Alhujaily, A. S. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.2.12285 · Cited by 4,382
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350 · cited 1×
“The phase 3 IMpassion130 trial (NCT02425891) tested the benefits of adding atezolizumab, an anti-PD-L1 monoclonal antibody, to nab-paclitaxel chemotherapy as compared to nab-paclitaxel alone as a first-line therapy for 902 mTNBC patients who were partitioned in a 1:1 ratio of 451 patients in each treatment arm [143,14…”
MethodCancer treatment and survivorship statistics, 2019
Miller, K. D., Nogueira, L., Mariotto, A. B., Rowland, J. H., Yabroff, K. R., Alfano, C. M., Jemal, A., Kramer, J. L., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21565 · Cited by 4,226
Foulkes, W. D., Smith, I. E., & Reis-Filho, J. S. (2010) · New England Journal of Medicine · doi:10.1056/nejmra1001389 · Cited by 4,157
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Pembrolizumab for Early Triple-Negative Breast Cancer
Schmid, P., Cortes, J., Pusztai, L., McArthur, H., Kümmel, S., Bergh, J., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910549 · Cited by 3,270
Targeting RAS signalling pathways in cancer therapy
Downward, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc969 · Cited by 3,256
Salgado, R., Denkert, C., Demaria, S., Sirtaine, N., Klauschen, F., Pruneri, G., Wienert, S., Van den Eynden, G., Baehner, F. L., Penault-Llorca, F., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdu450 · Cited by 3,113
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E., & Gianni, L. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.66 · Cited by 3,079 · cited 5×
“Chemotherapy can be given to treat high-risk and early-stage TNBC in the neoadjuvant and/or adjuvant setting [22,87,88].”
BackgroundInfluentialLiedtke, C., Mazouni, C., Hess, K. R., André, F., Tordai, A., Mejia, J. A., Symmans, W. F., Gonzalez-Angulo, A. M., Hennessy, B., Green, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.4147 · Cited by 2,892
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 2,880
von Minckwitz, G., Untch, M., Blohmer, J.-U., Costa, S. D., Eidtmann, H., Fasching, P. A., Gerber, B., Eiermann, W., Hilfrich, J., Huober, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.8595 · Cited by 2,659
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
André, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., Iwata, H., Conte, P., Mayer, I. A., Kaufman, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1813904 · Cited by 2,622
Olayioye, M. A. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,434
Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential
Sharma, P., & Allison, J. P. (2015) · Cell · doi:10.1016/j.cell.2015.03.030 · Cited by 2,345
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802905 · Cited by 2,175
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer
Prat, A., Parker, J. S., Karginova, O., Fan, C., Livasy, C., Herschkowitz, J. I., He, X., & Perou, C. M. (2010) · Breast Cancer Research · doi:10.1186/bcr2635 · Cited by 2,167
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Swain, S. M., Baselga, J., Kim, S.-B., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Heeson, S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1413513 · Cited by 2,164
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157 · cited 1×
“Interestingly, high TIL infiltration in the pre-treatment tumors was associated with the greatest benefit from the addition of carboplatin to NACT [122,126,127].”
BackgroundBreast cancer statistics, 2013
DeSantis, C., Ma, J., Bryan, L., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21203 · Cited by 2,143
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007) · Cancer · doi:10.1002/cncr.22618 · Cited by 2,067
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Masuda, N., Lee, S.-J., Ohtani, S., Im, Y.-H., Lee, E.-S., Yokota, I., Kuroi, K., Im, S.-A., Park, B.-W., Kim, S.-B., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612645 · Cited by 1,888
Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer
Ciriello, G., Gatza, M. L., Beck, A. H., Wilkerson, M. D., Rhie, S. K., Pastore, A., Zhang, H., McLellan, M., Yau, C., Kandoth, C., et al. (2015) · Cell · doi:10.1016/j.cell.2015.09.033 · Cited by 1,858
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Cancer Susceptibility and the Functions of BRCA1 and BRCA2
Venkitaraman, A. R. (2002) · Cell · doi:10.1016/s0092-8674(02)00615-3 · Cited by 1,713
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
Symmans, W. F., Peintinger, F., Hatzis, C., Rajan, R., Kuerer, H., Valero, V., Assad, L., Poniecka, A., Hennessy, B., Green, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.6823 · Cited by 1,654
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Roy, R., Chun, J., & Powell, S. N. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3181 · Cited by 1,469
Garrido-Castro, A. C., Lin, N. U., & Polyak, K. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1177 · Cited by 1,451
Lehmann, B. D., Jovanović, B., Chen, X., Estrada, M. V., Johnson, K. N., Shyr, Y., Moses, H. L., Sanders, M. E., & Pietenpol, J. A. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157368 · Cited by 1,426
PD-L1 Expression in Triple-Negative Breast Cancer
Mittendorf, E. A., Philips, A. V., Meric-Bernstam, F., Qiao, N., Wu, Y., Harrington, S., Su, X., Wang, Y., Gonzalez-Angulo, A. M., Akcakanat, A., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0127 · Cited by 1,396
Burstein, M. D., Tsimelzon, A., Poage, G. M., Covington, K. R., Contreras, A., Fuqua, S. A. W., Savage, M. I., Osborne, C. K., Hilsenbeck, S. G., Chang, J. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0432 · Cited by 1,392
PD-1 and PD-1 ligands: from discovery to clinical application
Okazaki, T., & Honjo, T. (2007) · International Immunology · doi:10.1093/intimm/dxm057 · Cited by 1,310
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women
DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21320 · Cited by 1,252
Schachter, J., Ribas, A., Long, G. V., Arance, A., Grob, J.-J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31601-x · Cited by 1,225
Schmid, P., Rugo, H. S., Adams, S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Henschel, V., Molinero, L., Chui, S. Y., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30689-8 · Cited by 1,216
Basal-Like Breast Cancer: A Critical Review
Rakha, E. A., Reis-Filho, J. S., & Ellis, I. O. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1748 · Cited by 1,164
Denkert, C., von Minckwitz, G., Brase, J. C., Sinn, B. V., Gade, S., Kronenwett, R., Pfitzner, B. M., Salat, C., Loi, S., Schmitt, W. D., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.1967 · Cited by 1,026
von Minckwitz, G., Schneeweiss, A., Loibl, S., Salat, C., Denkert, C., Rezai, M., Blohmer, J. U., Jackisch, C., Paepke, S., Gerber, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70160-3 · Cited by 1,022
Sikov, W. M., Berry, D. A., Perou, C. M., Singh, B., Cirrincione, C. T., Tolaney, S. M., Kuzma, C. S., Pluard, T. J., Somlo, G., Port, E. R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.0572 · Cited by 1,013
Heterogeneity in breast cancer
Polyak, K. (2011) · Journal of Clinical Investigation · doi:10.1172/jci60534 · Cited by 1,006
BRCA1 and BRCA2: 1994 and beyond
Narod, S. A., & Foulkes, W. D. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1431 · Cited by 967
Triple-negative breast cancer in African-American women: disparities versus biology
Dietze, E. C., Sistrunk, C., Miranda-Carboni, G., O'Regan, R., & Seewaldt, V. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3896 · Cited by 898
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874
Overall survival with ribociclib plus fulvestrant in advanced breast cancer
Slamon, D. J., Neven, P., Chia, S., Fasching, P. A., De Laurentiis, M., Im, S.-A., Petrakova, K., Bianchi, G. V., Esteva, F. J., Martín, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1911149 · Cited by 865
Treatment of HER2-positive breast cancer: current status and future perspectives
Arteaga, C. L., Sliwkowski, M. X., Osborne, C. K., Perez, E. A., Puglisi, F., & Gianni, L. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.177 · Cited by 861
Role of epidermal growth factor receptor in breast cancer
Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2289-9 · Cited by 806
DeSantis, C. E., Siegel, R. L., Sauer, A. G., Miller, K. D., Fedewa, S. A., Alcaraz, K. I., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21340 · Cited by 790
Triple-negative breast cancer: disease entity or title of convenience?
Carey, L., Winer, E., Viale, G., Cameron, D., & Gianni, L. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.154 · Cited by 783
Robson, M. E., Tung, N., Conte, P., Im, S.-A., Senkus, E., Xu, B., Masuda, N., Delaloge, S., Li, W., Armstrong, A., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz012 · Cited by 779
Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer
Tolaney, S. M., Barry, W. T., Dang, C. T., Yardley, D. A., Moy, B., Marcom, P. K., Albain, K. S., Rugo, H. S., Ellis, M., Shapira, I., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1406281 · Cited by 753
Gucalp, A., Tolaney, S., Isakoff, S. J., Ingle, J. N., Liu, M. C., Carey, L. A., Blackwell, K., Rugo, H., Nabell, L., Forero, A., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3327 · Cited by 749
Masuda, H., Baggerly, K. A., Wang, Y., Zhang, Y., Gonzalez-Angulo, A. M., Meric-Bernstam, F., Valero, V., Lehmann, B. D., Pietenpol, J. A., Hortobagyi, G. N., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0799 · Cited by 749
Toward understanding and exploiting tumor heterogeneity
Alizadeh, A. A., Aranda, V., Bardelli, A., Blanpain, C., Bock, C., Borowski, C., Caldas, C., Califano, A., Doherty, M., Elsner, M., et al. (2015) · Nature Medicine · doi:10.1038/nm.3915 · Cited by 746
Cancer statistics for African Americans, 2019
DeSantis, C. E., Miller, K. D., Goding Sauer, A., Jemal, A., & Siegel, R. L. (2019) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21555 · Cited by 743
Symmans, W. F., Wei, C., Gould, R., Yu, X., Zhang, Y., Liu, M., Walls, A., Bousamra, A., Ramineni, M., Sinn, B., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.1010 · Cited by 711
Lin, N. U., Vanderplas, A., Hughes, M. E., Theriault, R. L., Edge, S. B., Wong, Y., Blayney, D. W., Niland, J. C., Winer, E. P., & Weeks, J. C. (2012) · Cancer · doi:10.1002/cncr.27581 · Cited by 695
Triple-negative breast cancer—current status and future directions
Gluz, O., Liedtke, C., Gottschalk, N., Pusztai, L., Nitz, U., & Harbeck, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdp492 · Cited by 687
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Sosman, J. A., Atkins, M. B., Leming, P. D., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.2187 · Cited by 619
Iqbal, J., Ginsburg, O., Rochon, P. A., Sun, P., & Narod, S. A. (2015) · JAMA · doi:10.1001/jama.2014.17322 · Cited by 614
Differences in Breast Cancer Survival by Molecular Subtypes in the United States
Howlader, N., Cronin, K. A., Kurian, A. W., & Andridge, R. (2018) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-17-0627 · Cited by 598
Triple-negative breast cancer: epidemiological considerations and recommendations
Boyle, P. (2012) · Annals of Oncology · doi:10.1093/annonc/mds187 · Cited by 593
Gonzalez-Angulo, A. M., Timms, K. M., Liu, S., Chen, H., Litton, J. K., Potter, J., Lanchbury, J. S., Stemke-Hale, K., Hennessy, B. T., Arun, B. K., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2560 · Cited by 573
Clinical management of breast cancer heterogeneity
Zardavas, D., Irrthum, A., Swanton, C., & Piccart, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.73 · Cited by 570
Pattern of metastatic spread in triple-negative breast cancer
Dent, R., Hanna, W. M., Trudeau, M., Rawlinson, E., Sun, P., & Narod, S. A. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-0086-2 · Cited by 554
Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors.
Roger, P., Sahla, M. E., Mäkelä, S., Gustafsson, J. A., Baldet, P., & Rochefort, H. (2001) · PubMed · Cited by 551
Loi, S., Dushyanthen, S., Beavis, P. A., Salgado, R., Denkert, C., Savas, P., Combs, S., Rimm, D. L., Giltnane, J. M., Estrada, M. V., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1125 · Cited by 536
Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
von Minckwitz, G., Eidtmann, H., Rezai, M., Fasching, P. A., Tesch, H., Eggemann, H., Schrader, I., Kittel, K., Hanusch, C., Kreienberg, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111065 · Cited by 530
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
NCCN Guidelines Insights: Breast Cancer, Version 1.2017
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0044 · Cited by 529
Self-citationCarey, L. A., Rugo, H. S., Marcom, P. K., Mayer, E. L., Esteva, F. J., Ma, C. X., Liu, M. C., Storniolo, A. M., Rimawi, M. F., Forero-Torres, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.5579 · Cited by 499
Cellular Heterogeneity and Molecular Evolution in Cancer
Almendro, V., Marusyk, A., & Polyak, K. (2013) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-020712-163923 · Cited by 498
Intratumor Heterogeneity: Seeing the Wood for the Trees
Yap, T. A., Gerlinger, M., Futreal, P. A., Pusztai, L., & Swanton, C. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003854 · Cited by 490
Kim, S.-B., Dent, R., Im, S.-A., Espié, M., Blau, S., Tan, A. R., Isakoff, S. J., Oliveira, M., Saura, C., Wongchenko, M. J., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30450-3 · Cited by 478
Davies, B. R., Greenwood, H., Dudley, P., Crafter, C., Yu, D.-H., Zhang, J., Li, J., Gao, B., Ji, Q., Maynard, J., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0824-t · Cited by 471
Targeting the ERBB family in cancer: couples therapy
Tebbutt, N., Pedersen, M. W., & Johns, T. G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3559 · Cited by 466
Breast Cancer Screening and Diagnosis
Bevers, T. B., Anderson, B. O., Bonaccio, E., Buys, S., Daly, M. B., Dempsey, P. J., Farrar, W. B., Fleming, I., Garber, J. E., Harris, R. E., et al. (2009) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2009.0070 · Cited by 465
Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer
Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Robidoux, A., Atkins, J. N., Baez-Diaz, L., Brufsky, A. M., Mehta, R. S., Fehrenbacher, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1111097 · Cited by 461
Self-citationDieci, M. V., Criscitiello, C., Goubar, A., Viale, G., Conte, P., Guarneri, V., Ficarra, G., Mathieu, M. C., Delaloge, S., Curigliano, G., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt556 · Cited by 460
PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated Cells
Noordermeer, S. M., & van Attikum, H. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2019.07.008 · Cited by 456
The Landscape of Targeted Therapies in TNBC
Vagia, E., Mahalingam, D., & Cristofanilli, M. (2020) · Cancers · doi:10.3390/cancers12040916 · Cited by 450
Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review
Costa, R. L. B., Han, H. S., & Gradishar, W. J. (2018) · Breast Cancer Research and Treatment · doi:10.1007/s10549-018-4697-y · Cited by 439
Esserman, L. J., Berry, D. A., DeMichele, A., Carey, L., Davis, S. E., Buxton, M., Hudis, C., Gray, J. W., Perou, C., Yau, C., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.2779 · Cited by 438
Isakoff, S. J., Mayer, E. L., He, L., Traina, T. A., Carey, L. A., Krag, K. J., Rugo, H. S., Liu, M. C., Stearns, V., Come, S. E., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.6660 · Cited by 436
Dieci, M. V., Radosevic-Robin, N., Fineberg, S., van den Eynden, G., Ternes, N., Penault-Llorca, F., Pruneri, G., D’Alfonso, T. M., Demaria, S., Castaneda, C., et al. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.003 · Cited by 433
Cameron, D., Brown, J., Dent, R., Jackisch, C., Mackey, J., Pivot, X., Steger, G. G., Suter, T. M., Toi, M., Parmar, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70335-8 · Cited by 432
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Ashworth, A., & Lord, C. J. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0055-6 · Cited by 420
Schmid, P., Salgado, R., Park, Y. H., Muñoz-Couselo, E., Kim, S. B., Sohn, J., Im, S.-A., Foukakis, T., Kuemmel, S., Dent, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.072 · Cited by 413
Bardia, A., Mayer, I. A., Diamond, J. R., Moroose, R. L., Isakoff, S. J., Starodub, A. N., Shah, N. C., O’Shaughnessy, J., Kalinsky, K., Guarino, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.8297 · Cited by 412
Schmid, P., Abraham, J., Chan, S., Wheatley, D., Brunt, A. M., Nemsadze, G., Baird, R. D., Park, Y. H., Hall, P. S., Perren, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.00368 · Cited by 391
ERβ Inhibits Proliferation and Invasion of Breast Cancer Cells
Lazennec, G., Bresson, D., Lucas, A., Chauveau, C., & Vignon, F. (2001) · Endocrinology · doi:10.1210/endo.142.9.8395 · Cited by 380
Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
Saini, K. S., Loi, S., de Azambuja, E., Metzger-Filho, O., Saini, M. L., Ignatiadis, M., Dancey, J. E., & Piccart-Gebhart, M. J. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.03.009 · Cited by 374
Baselga, J., Gómez, P., Greil, R., Braga, S., Climent, M. A., Wardley, A. M., Kaufman, B., Stemmer, S. M., Pêgo, A., Chan, A., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.2408 · Cited by 363
The I-SPY 1 TRIAL Investigators, Esserman, L. J., Berry, D. A., Cheang, M. C. U., Yau, C., Perou, C. M., Carey, L., DeMichele, A., Gray, J. W., Conway-Dorsey, K., et al. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-011-1895-2 · Cited by 362
Recent advances in triple negative breast cancer: the immunotherapy era
Marra, A., Viale, G., & Curigliano, G. (2019) · BMC Medicine · doi:10.1186/s12916-019-1326-5 · Cited by 355
Understanding and treating triple-negative breast cancer
Carey, L., & Anders, C. (2021) · PubMed · doi:10.17615/85ph-f542 · Cited by 351
Triple-Negative Breast Cancer: Role of Specific Chemotherapy Agents
Isakoff, S. J. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181d24ff7 · Cited by 348
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
Corkery, B., Crown, J., Clynes, M., & O'Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348
Cimino-Mathews, A., Thompson, E., Taube, J. M., Ye, X., Lu, Y., Meeker, A., Xu, H., Sharma, R., Lecksell, K., Cornish, T. C., et al. (2016) · Human Pathology · doi:10.1016/j.humpath.2015.09.003 · Cited by 336
The comings and goings of PARP-1 in response to DNA damage
Pascal, J. M. (2018) · DNA Repair · doi:10.1016/j.dnarep.2018.08.022 · Cited by 335
Targeting the PI3-kinase pathway in triple-negative breast cancer
Pascual, J., & Turner, N. C. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz133 · Cited by 333
The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
Goldenberg, D. M., Stein, R., & Sharkey, R. M. (2018) · Oncotarget · doi:10.18632/oncotarget.25615 · Cited by 327
Triple negative breast cancer: unmet medical needs
Pal, S. K., Childs, B. H., & Pegram, M. (2011) · Breast Cancer Research and Treatment · doi:10.1007/s10549-010-1293-1 · Cited by 322
Jézéquel, P., Loussouarn, D., Guérin-Charbonnel, C., Campion, L., Vanier, A., Gouraud, W., Lasla, H., Guette, C., Valo, I., Verrièle, V., et al. (2015) · Breast Cancer Research · doi:10.1186/s13058-015-0550-y · Cited by 321
Outcome and molecular landscape of patients with PIK3CA-mutated metastatic breast cancer
Mosele, F., Stefanovska, B., Lusque, A., Tran Dien, A., Garberis, I., Droin, N., Le Tourneau, C., Sablin, M.-P., Lacroix, L., Enrico, D., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2019.11.006 · Cited by 314
Radovich, M., Jiang, G., Hancock, B. A., Chitambar, C., Nanda, R., Falkson, C., Lynce, F. C., Gallagher, C., Isaacs, C., Blaya, M., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2295 · Cited by 307
Echeverria, G. V., Ge, Z., Seth, S., Zhang, X., Jeter-Jones, S., Zhou, X., Cai, S., Tu, Y., McCoy, A., Peoples, M., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aav0936 · Cited by 306
Health Disparities and Triple-Negative Breast Cancer in African American Women: A Review
Newman, L. A., & Kaljee, L. M. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2017.0005 · Cited by 304
Tissue-resident memory T cells in breast cancer control and immunotherapy responses
Byrne, A., Savas, P., Sant, S., Li, R., Virassamy, B., Luen, S. J., Beavis, P. A., Mackay, L. K., Neeson, P. J., & Loi, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0333-y · Cited by 301
Lin, J., Sampath, D., Nannini, M. A., Lee, B. B., Degtyarev, M., Oeh, J., Savage, H., Guan, Z., Hong, R., Kassees, R., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3072 · Cited by 294
Biology and Management of Patients With Triple-Negative Breast Cancer
Sharma, P. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0067 · Cited by 294
Blum, J. L., Flynn, P. J., Yothers, G., Asmar, L., Geyer, C. E., Jacobs, S. A., Robert, N. J., Hopkins, J. O., O'Shaughnessy, J. A., Dang, C. T., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.4147 · Cited by 294
Bonnefoi, H., Grellety, T., Tredan, O., Saghatchian, M., Dalenc, F., Mailliez, A., L'Haridon, T., Cottu, P., Abadie-Lacourtoisie, S., You, B., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw067 · Cited by 283
Huo, D., Hu, H., Rhie, S. K., Gamazon, E. R., Cherniack, A. D., Liu, J., Yoshimatsu, T. F., Pitt, J. J., Hoadley, K. A., Troester, M., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0595 · Cited by 283
Genetic Markers in Triple-Negative Breast Cancer
Sporikova, Z., Koudelakova, V., Trojanec, R., & Hajduch, M. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.023 · Cited by 262
O’Keefe, E. B., Meltzer, J. P., & Bethea, T. N. (2015) · Frontiers in Public Health · doi:10.3389/fpubh.2015.00051 · Cited by 259
García-Martínez, E., Gil, G. L., Benito, A. C., González-Billalabeitia, E., Conesa, M. A. V., García, T. G., García-Garre, E., Vicente, V., & de la Peña, F. A. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0488-5 · Cited by 253
Neoadjuvant treatment of breast cancer
Thompson, A. M., & Moulder-Thompson, S. L. (2012) · Annals of Oncology · doi:10.1093/annonc/mds324 · Cited by 251
Determination of Neuronal Cell Fate: Lessons from the R7 Neuron of Drosophila
Zipursky, S. L., & Rubin, G. M. (1994) · Annual Review of Neuroscience · doi:10.1146/annurev.ne.17.030194.002105 · Cited by 247
Vaz-Luis, I., Ottesen, R. A., Hughes, M. E., Mamet, R., Burstein, H. J., Edge, S. B., Gonzalez-Angulo, A. M., Moy, B., Rugo, H. S., Theriault, R. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1608 · Cited by 244
Ocean, A. J., Starodub, A. N., Bardia, A., Vahdat, L. T., Isakoff, S. J., Guarino, M., Messersmith, W. A., Picozzi, V. J., Mayer, I. A., Wegener, W. A., et al. (2017) · Cancer · doi:10.1002/cncr.30789 · Cited by 244
Bossuyt, V., Provenzano, E., Symmans, W. F., Boughey, J. C., Coles, C., Curigliano, G., Dixon, J. M., Esserman, L. J., Fastner, G., Kuehn, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv161 · Cited by 240
A review of PARP inhibitors: from bench to bedside
Underhill, C., Toulmonde, M., & Bonnefoi, H. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq322 · Cited by 240
Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States
Mougalian, S. S., Soulos, P. R., Killelea, B. K., Lannin, D. R., Abu‐Khalaf, M. M., DiGiovanna, M. P., Sanft, T. B., Pusztai, L., Gross, C. P., & Chagpar, A. B. (2015) · Cancer · doi:10.1002/cncr.29348 · Cited by 237
Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry
Brewster, A. M., Chavez-MacGregor, M., & Brown, P. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70364-x · Cited by 235
Beckers, R. K., Selinger, C. I., Vilain, R., Madore, J., Wilmott, J. S., Harvey, K., Holliday, A., Cooper, C. L., Robbins, E., Gillett, D., et al. (2016) · Histopathology · doi:10.1111/his.12904 · Cited by 231
Tang, A. H., Neufeld, T. P., Kwan, E., & Rubin, G. M. (1997) · Cell · doi:10.1016/s0092-8674(00)80506-1 · Cited by 230
Self-citationMiles, D. W., Diéras, V., Cortés, J., Duenne, A.-A., Yi, J., & O'Shaughnessy, J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt276 · Cited by 228
In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival
Ladoire, S., Mignot, G., Dabakuyo, S., Arnould, L., Apetoh, L., Rébé, C., Coudert, B., Martin, F., Bizollon, M. H., Vanoli, A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2866 · Cited by 226
Karn, T., Denkert, C., Weber, K. E., Holtrich, U., Hanusch, C., Sinn, B. V., Higgs, B. W., Jank, P., Sinn, H. P., Huober, J., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.015 · Cited by 224
PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review
Planes-Laine, G., Rochigneux, P., Bertucci, F., Chrétien, A.-S., Viens, P., Sabatier, R., & Gonçalves, A. (2019) · Cancers · doi:10.3390/cancers11071033 · Cited by 221
Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy
King, T. A., & Morrow, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.63 · Cited by 215
Aberrant function of the Ras signal transduction pathway in human breast cancer
Clark, G. J., & Der, C. J. (1995) · Breast Cancer Research and Treatment · doi:10.1007/bf00694753 · Cited by 213
Involvement of Ras Activation in Human Breast Cancer Cell Signaling, Invasion, and Anoikis
Eckert, L. B., Repasky, G. A., Ülkü, A. S., McFall, A., Zhou, H., Sartor, C. I., & Der, C. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0396 · Cited by 207
Therapeutic targets of triple‐negative breast cancer: a review
Jamdade, V. S., Sethi, N., Mundhe, N. A., Kumar, P., Lahkar, M., & Sinha, N. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13211 · Cited by 205
Expression of PD-L1 and prognosis in breast cancer: a meta-analysis
Zhang, M., Sun, H., Zhao, S., Wang, Y., Pu, H., Wang, Y., & Zhang, Q. (2017) · Oncotarget · doi:10.18632/oncotarget.15532 · Cited by 201
Luen, S. J., Salgado, R., Dieci, M. V., Vingiani, A., Curigliano, G., Gould, R. E., Castaneda, C., D’Alfonso, T., Sanchez, J., Cheng, E., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy547 · Cited by 198
Tevaarwerk, A. J., Gray, R. J., Schneider, B. P., Smith, M. L., Wagner, L. I., Fetting, J. H., Davidson, N., Goldstein, L. J., Miller, K. D., & Sparano, J. A. (2013) · Cancer · doi:10.1002/cncr.27819 · Cited by 196
Rugo, H. S., André, F., Yamashita, T., Cerda, H., Toledano, I., Stemmer, S. M., Jurado, J. C., Juric, D., Mayer, I., Ciruelos, E. M., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.001 · Cited by 193
Santonja, A., Sánchez-Muñoz, A., Lluch, A., Chica-Parrado, M. R., Albanell, J., Chacón, J. I., Antolín, S., Jerez, J. M., Haba, J. D. L., de Luque, V., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25413 · Cited by 192
Basho, R. K., Gilcrease, M., Murthy, R. K., Helgason, T., Karp, D. D., Meric-Bernstam, F., Hess, K. R., Herbrich, S. M., Valero, V., Albarracin, C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.5281 · Cited by 188
Poly(ADP-ribose) polymerase-1 antagonizes DNA resection at double-strand breaks
Caron, M.-C., Sharma, A. K., O’Sullivan, J., Myler, L. R., Ferreira, M. T., Rodrigue, A., Coulombe, Y., Ethier, C., Gagné, J.-P., Langelier, M.-F., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10741-9 · Cited by 185
Ras activation in human breast cancer
von Lintig, F. C., Dreilinger, A. D., Varki, N. M., Wallace, A. M., Casteel, D. E., & Boss, G. R. (2000) · Breast Cancer Research and Treatment · doi:10.1023/a:1006491619920 · Cited by 184
Distinct expression patterns of ER and ER in normal human mammary gland
Speirs, V., Skliris, G. P., Burdall, S. E., & Carder, P. J. (2002) · Journal of Clinical Pathology · doi:10.1136/jcp.55.5.371 · Cited by 180
Emerging targeted agents in metastatic breast cancer
Zardavas, D., Baselga, J., & Piccart, M. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.29 · Cited by 178
Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
Lee, J. S., Yost, S. E., & Yuan, Y. (2020) · Cancers · doi:10.3390/cancers12061404 · Cited by 178
Triple-Negative Breast Cancer: Molecular Subtypes and New Targets for Therapy
Lehmann, B. D., Pietenpol, J. A., & Tan, A. R. (2015) · American Society of Clinical Oncology Educational Book · doi:10.14694/edbook_am.2015.35.e31 · Cited by 176
Park, J. H., Ahn, J. H., & Kim, S. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000357 · Cited by 170
Zhao, C., Lam, E. W.-F., Sunters, A., Enmark, E., De Bella, M. T., Coombes, R. C., Gustafsson, J.-Å., & Dahlman-Wright, K. (2003) · Oncogene · doi:10.1038/sj.onc.1207100 · Cited by 166
Angiogenesis and Antiangiogenesis in Triple-Negative Breast cancer
Ribatti, D., Nico, B., Ruggieri, S., Tamma, R., Simone, G., & Mangia, A. (2016) · Translational Oncology · doi:10.1016/j.tranon.2016.07.002 · Cited by 166
Bear, H. D., Tang, G., Rastogi, P., Geyer, C. E., Liu, Q., Robidoux, A., Báez-Díaz, L., Brufsky, A., Mehta, R. S., Fehrenbacher, L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00041-8 · Cited by 165
Self-citationBaselga, J., Segalla, J. G. M., Roché, H., del Giglio, A., Pinczowski, H., Ciruelos, E. M., Filho, S. C., Gómez, P., Van Eyll, B., Bermejo, B., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.7771 · Cited by 164
Prat, A., Fan, C., Fernández, A., Hoadley, K. A., Martinello, R., Vidal, M., Viladot, M., Pineda, E., Arance, A., Muñoz, M., et al. (2015) · BMC Medicine · doi:10.1186/s12916-015-0540-z · Cited by 164
Drug repurposing for breast cancer therapy: Old weapon for new battle
Aggarwal, S., Verma, S. S., Aggarwal, S., & Gupta, S. C. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.09.012 · Cited by 163
Madic, J., Kiialainen, A., Bidard, F., Birzele, F., Ramey, G., Leroy, Q., Frio, T. R., Vaucher, I., Raynal, V., Bernard, V., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.29265 · Cited by 160
Molecular stratification within triple-negative breast cancer subtypes
Wang, D., Jiang, Z., Ben‐David, Y., Woodgett, J. R., & Zacksenhaus, E. (2019) · Scientific Reports · doi:10.1038/s41598-019-55710-w · Cited by 159
Pandy, J. G. P., Balolong-Garcia, J. C., Cruz-Ordinario, M. V. B., & Que, F. V. (2019) · BMC Cancer · doi:10.1186/s12885-019-6253-5 · Cited by 157
Jovanović, B., Mayer, I. A., Mayer, E. L., Abramson, V. G., Bardia, A., Sanders, M. E., Kuba, M. G., Estrada, M. V., Beeler, J. S., Shaver, T. M., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3055 · Cited by 156
Dotzlaw, H., Leygue, E., Watson, P. H., & Murphy, L. C. (1999) · PubMed · Cited by 153
Advances in the use of PARP inhibitor therapy for breast cancer
McCann, K. E., & Hurvitz, S. A. (2018) · Drugs in Context · doi:10.7573/dic.212540 · Cited by 139
Rugo, H. S., Bardia, A., Tolaney, S. M., Arteaga, C. L., Cortés, J., Sohn, J., Marmé, F., Hong, Q., Delaney, R., Hafeez, A., et al. (2020) · Future Oncology · doi:10.2217/fon-2020-0163 · Cited by 137
Therapeutic landscape in mutational triple negative breast cancer
Shi, Y., Jin, J., Ji, W., & Guan, X. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0850-9 · Cited by 135
Williford, J., Ishihara, J., Ishihara, A., Mansurov, A., Hosseinchi, P., Marchell, T. M., Potin, L., Swartz, M. A., & Hubbell, J. A. (2019) · Science Advances · doi:10.1126/sciadv.aay1357 · Cited by 134
Neoadjuvant Therapy in Early Breast Cancer: Treatment Considerations and Common Debates in Practice
Cain, H. J., Macpherson, I. R., Beresford, M. J., Pinder, S. E., Pong, J. Z., & Dixon, J. M. (2017) · Clinical Oncology · doi:10.1016/j.clon.2017.06.003 · Cited by 131
Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy
Sheri, A., Smith, I. E., Johnston, S. R. D., A’Hern, R., Nerurkar, A. Y., Jones, R. L., Hills, M., DETRE, S. I., Pinder, S. E., Symmans, W. F., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu508 · Cited by 125
Current Approaches and Challenges in Monitoring Treatment Responses in Breast Cancer
Graham, L. J., Shupe, M. P., Schneble, E. J., Flynt, F. L., Clemenshaw, M. N., Kirkpatrick, A. D., Gallagher, C., Nissan, A., Henry, L. R., Stojadinovic, A., et al. (2014) · Journal of Cancer · doi:10.7150/jca.7047 · Cited by 124
Hu, C., Polley, E. C., Yadav, S., Lilyquist, J., Shimelis, H., Na, J., Hart, S. N., Goldgar, D. E., Shah, S. H., Pesaran, T. F., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa023 · Cited by 124
Bell, R., Brown, J. M., Parmar, M., Toi, M., Suter, T. M., Steger, G. G., Pivot, X. B., Mackey, J. R., Jackisch, C., Dent, R. A., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw665 · Cited by 118
Schroeder, M. C., Rastogi, P., Geyer, C. E., Miller, L. D., & Thomas, A. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0398 · Cited by 114
Therapies for triple negative breast cancer
Andreopoulou, E., Schweber, S. J., Sparano, J. A., & McDaid, H. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032246 · Cited by 113
Leon-Ferre, R. A., Polley, M. C., Liu, H., Gilbert, J. A., Cafourek, V., Hillman, D. W., Elkhanany, A. M., Akinhanmi, M. O., Lilyquist, J., Thomas, A., et al. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4499-7 · Cited by 111
Self-citationPARP inhibitors stumble in breast cancer
Guha, M. (2011) · Nature Biotechnology · doi:10.1038/nbt0511-373 · Cited by 110
Fasching, P. A., Loibl, S., Hu, C., Hart, S. N., Shimelis, H., Moore, R. M., Schem, C., Tesch, H., Untch, M., Hilfrich, J., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.2285 · Cited by 106
Biswas, T., Efird, J. T., Prasad, S., Jindal, C., & Walker, P. R. (2017) · Oncotarget · doi:10.18632/oncotarget.22521 · Cited by 105
Tomioka, N., Azuma, M., Ikarashi, M., YAMAMOTO, M., Sato, M., Watanabe, K., Yamashiro, K., & Takahashi, M. (2017) · Breast Cancer · doi:10.1007/s12282-017-0781-0 · Cited by 103
The Neoadjuvant Model Is Still the Future for Drug Development in Breast Cancer
DeMichele, A., Yee, D., Berry, D. A., Albain, K. S., Benz, C. C., Boughey, J. C., Buxton, M., Chia, S., Chien, A. J., Hui, J. Y. C., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1760 · Cited by 96
Self-citationAdams, S., Dieras, V. C., Barrios, C. H., Winer, E. P., Schneeweiß, A., Iwata, H., Loi, S., Patel, S., Henschel, V., Chui, S. Y., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.02.003 · Cited by 94
Cited by
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Obidiro, O., Battogtokh, G., & Akala, E. O. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15071796 · Cited by 511
Gong, J., Cheng, D., Liu, C., Wu, S., Sun, N., Zhao, L., Li, J., Xing, Y., & Zhao, J. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202404184 · Cited by 53
Metadata
- Authors
- Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., Samli, B., Jansen, R. J., Petricoin, E. F., Goetz, M. P., Bear, H. D., & Tang, A. H.
- Venue
- Cancers
- Publisher
- MDPI AG
- Published
- 2020-08-24
- Volume
- 12
- Issue
- 9
- Pages
- 2392
- ISSN
- 2072-6694 (ISSN-L)
- OpenAlex
- W3081189407
- Cited by
- 331
- References
- 266
- FWCI
- 13.16
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.